Good morning :)
$
₹
Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc

COLL

NASDAQ
Asset Logo

Collegium Pharmaceutical Inc

COLL

NASDAQ
$23.640.36% (-0.08)
$
₹
$23.640.36% (-0.08)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Drug Manufacturers - Specialty & Generic

Small Cap

With a market cap of $770.9M the stock is ranked 2931

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

18.64
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

2.48
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.27
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0.70
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

5.93%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 8 analysts reports

Buy
7 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+106.49%

Earnings Growth

+5.64%

Rev. Growth

+6.73%

See Detailed Forecast

Company Profile

Company Profile

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
46.00
46.00
1Y Return
56.59%
56.59%
Buy Reco %
83.87
83.87
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
41.05
41.05
1Y Return
48.81%
48.81%
Buy Reco %
69.56
69.56
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
149.85
149.85
1Y Return
79.29%
79.29%
Buy Reco %
67.85
67.85
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
30.82
30.82
1Y Return
31.97%
31.97%
Buy Reco %
41.66
41.66
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
26.39
26.39
1Y Return
11.26%
11.26%
Buy Reco %
75.00
75.00
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 106.49% growth, versus a trailing 3-year CAGR of 2.40%.

2026
Current$23.73Baseline
Analyst Target - 1 year
Target$49+106.49%

All values in $

202220232024202520262027$29.13$37.39$45.64Target+106.49%
2026
Current$23.73Baseline
Analyst Target - 1 year
Target$49+106.49%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 6.73% growth, versus a trailing 3-year CAGR of 18.94%.

2025
Current$780.56Baseline
Forecast for Dec 2026
High$837.3+7.27%
Average$833.10+6.73%
Low$826+5.82%

All values in $ Million

202120222023202420252026276.86463.93566.76631.44780.56Low+5.82%Average+6.73%High+7.27%
2025
Current$780.56Baseline
Forecast for Dec 2026
High$837.3+7.27%
Average$833.10+6.73%
Low$826+5.82%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

Lower earnings growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 5.64% growth, versus a trailing 3-year CAGR of 32.87%.

2025
Current$7.06Baseline
Forecast for Dec 2026
High$7.69+8.92%
Average$7.46+5.64%
Low$7.2+1.98%

All values in $

2021202220232024202520262.043.015.56.457.06Low+1.98%Average+5.64%High+8.92%
2025
Current$7.06Baseline
Forecast for Dec 2026
High$7.69+8.92%
Average$7.46+5.64%
Low$7.2+1.98%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

209.3
31.5
205.4
16.9
193.5
14.4
199.8
-15
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue144.92145.27159.30181.94177.75188209.36205.44193.52199.87
Net Income27.7119.609.3312.532.4111.9831.5016.9614.49-15.05
Net Profit Margin19.12%13.49%5.85%6.88%1.35%6.37%15.04%8.25%7.49%-7.53%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareDrug Manufacturers - Specialty & Generic

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Collegium Pharmaceutical Inc 18.642.480.70
Eli Lilly and Company46.0031.351.35
Johnson & Johnson41.058.063.07
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare COLL with any stock or ETF
Compare COLL with any stock or ETF
Comparing from
COLL
LLY
JNJ
Loading...

Frequently asked questions

  1. Collegium Pharmaceutical Inc (COLL) share price today is $23.64 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $24.33 and a day low of $23.43.

  2. Collegium Pharmaceutical Inc stock trades on NASDAQ under the ticker symbol COLL.

  3. Collegium Pharmaceutical Inc's market capitalization is $770.91M as of November 5, 2026 at 2:29 AM IST.

  4. Collegium Pharmaceutical Inc's price-to-earnings (P/E) ratio is 18.64 as of November 4, 2026.

  5. Collegium Pharmaceutical Inc's price-to-book (P/B) ratio is 2.48 as of November 4, 2026.

  6. Yes, You can buy Collegium Pharmaceutical Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Collegium Pharmaceutical Inc shares in three steps: 1. Search Collegium Pharmaceutical Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Collegium Pharmaceutical Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Collegium Pharmaceutical Inc (COLL) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.4229 shares at the current price of $23.64.

Loading...